EvolveImmune Therapeutics is Drug Discovery in United States that focus on Deevloper business. Founded in 2019. They cover business area such as Deevloper, novel immunotherapy, treatment, unmet need, oncology and autoimmune disease, a pipeline, novel therapeutic candidate, numerous target, multiple immune cell type, its proprietary, vivo target discovery platform, doctor, physician, patient, autoimmune and various other disease.
2019
( 5 years old in 2024 )
Deevloper
-
23 Business Park Drive
Branford, CT 06405
United States
Private
Deevlopernovel immunotherapytreatmentunmet needoncology and autoimmune diseasea pipelinenovel therapeutic candidatenumerous targetmultiple immune cell typeits proprietaryvivo target discovery platformdoctorphysicianpatientautoimmune and various other disease
* We use standard office opening hours in near EvolveImmune Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
EvolveImmune Therapeutics is Drug Discovery business from United States that founded in 2019 (5 years old in 2024), EvolveImmune Therapeutics business is focusing on Deevloper.
EvolveImmune Therapeutics headquarter office and corporate office address is located in 23 Business Park Drive Branford, CT 06405 United States.
EvolveImmune Therapeutics was founded in United States.
In 2024, EvolveImmune Therapeutics is currently focus on Deevloper sector.
Above is snippet of Google Trends for "Deevloper" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with EvolveImmune Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
